| Number | Title | Target
accrual |
| EORTC Brain Tumor Group |
22042
26042 | Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma : a Phase II and observation study Study Coordinator: Damien Weber, Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie, Geneve
| 54 |
26053
22054 | Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON intergroup trial. Study Coordinators: Brigitta Baumert, MediClin Robert Janker Klinik, Bonn Martin J. van den Bent, Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam
| 748 |
26062
22061 | A randomized phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients Study Coordinator: Alba Brandes, Ospedale Bellaria, Bologna
| 560 |
26091
TAVAREC | Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial. Study Coordinator: Martin J. van den Bent, Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam
| 144 |
26101
| Phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma. Study Coordinator: Wolfgang Wick, Universitaetsklinikum Heidelberg - UniversitaetsKlinikum Heidelberg - Head Hospital, Heidelberg
| 249 |
| EORTC Breast Cancer Group |
10085
Male BC | Clinical and biological characterization of Male Breast Cancer : an international retrospective EORTC, BIG and NABCG intergroup study. Study Coordinators: Fatima Cardoso, Champalimaud Cancer Center, Lisboa Sharon Hermes Giordano, Md Anderson Cancer Center, Houston
| 1800 |
10112
Aphinity | A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer. Study Coordinator: Fatima Cardoso, Champalimaud Cancer Center, Lisboa
| 3806 |
22085
10083 | A randomized phase III study of radiation doses and fractionation schedules for ductal carcinoma in situ (DCIS) of the breast. Study Coordinator: Helen Westenberg, Arnhem's Radiotherapeutisch Instituut, Arnhem
| 610 |
90091
10093 | TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) ("Treat CTC" trial) Study Coordinator: Michail Ignatiadis, Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels
| 250 |
| EORTC Cancer in Elderly Task Force |
40085
75083 | Treatment of patients with KRAS wild type advanced colorectal cancer with 5-fluorouracil (5-FU) or 5-FU plus an Epidermal Growth Factor Receptor inhibitor (cetuximab) based on a Comprehensive Geriatric Assessment. Study Coordinator: Marc Peeters, Universitair Ziekenhuis Antwerpen, Edegem
| 150 |
| EORTC Children's Leukemia Group |
58051
Interfant | International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia Study Coordinator: Alina Ferster, Hopital Universitaire Des Enfants Reine Fabiola, Brussels
| 445 |
58081
| Translational research - observational study for identification of new possible prognostic factors and future therapeutic targets in children with acute lymphoblastic leukaemia (ALL). Study Coordinator: Helene Cave, Assistance Publique - Hôpitaux de Paris - Hopital Robert Debre AP-HP, Paris
| 800 |
58LAE
| Assessment of the long term outcome of childhood ALL patients enrolled in EORTC CLG trials between 1971 and 1998 Study Coordinator: Caroline Piette, Centre Hospitalier Regional De La Citadelle, Liege
| 3138 |
| EORTC Gastrointestinal Tract Cancer Group |
40071
| Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction, metastatic or not amenable to curative surgery according to HER2 and EGFR status: a randomized phase II trial. Study Coordinator: Arnaud Roth, Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie, Geneve
| 192 |
40084
22084 | A phase III trial evaluating both Erlotinib and Chemoradiation as adjuvant treatment for patients with resected head of pancreas adenocarcinoma Study Coordinator: Jean-Luc Van Laethem, Hôpitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme, Brussels
| 950 |
40085
75083 | Treatment of patients with KRAS wild type advanced colorectal cancer with 5-fluorouracil (5-FU) or 5-FU plus an Epidermal Growth Factor Receptor inhibitor (cetuximab) based on a Comprehensive Geriatric Assessment. Study Coordinator: Marc Peeters, Universitair Ziekenhuis Antwerpen, Edegem
| 150 |
40091
BOS 2 | Randomized phase II trial evaluating the efficacy of FOLFOX alone, FOLFOX plus bevacizumab and FOLFOX plus panitumumab as perioperative treatment in patients with resectable liver metastases from wild type KRAS colorectal cancer Study Coordinators: Stephane Benoist, Assistance Publique - Hôpitaux de Paris - Hopital De Bicetre AP-HP, Le Kremlin Bicetre Bernard Nordlinger, CHU Ambroise Pare AP-HP, Boulogne-Billancourt
| 360 |
40101
POWER | An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced or metastatic esophageal squamous cell cancer (ESCC) Study Coordinator: Baruch Brenner, Rabin Medical Center - Tel Aviv University, Petah Tiqva
| 300 |
| EORTC Genito-Urinary Cancers Group |
22043
30041 | Immediate or early salvage post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus immediate or early salvage post-operative external radiotherapy alone in pT3a-b R0-1 cNOMO/pT2R1 cN0M0, Gleason score 5-10 prostatic carcinoma. A phase III study. Study Coordinators: Michel Bolla, CHU de Grenoble - La Tronche - Hôpital A. Michallon, Grenoble Steven Joniau, U.Z. Leuven - Campus Gasthuisberg, Leuven
| 600 |
30073
SURTIME | Randomized Phase III trial comparing immediate versus deferred nephrectomy in patients with synchronous metastatic renal cell carcinoma. Study Coordinators: Axel Bex, The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam John B.A.G. Haanen, The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam
| 458 |
| EORTC Gynecological Cancer Group |
55092
| Phase IB-II, open label, multicentre feasibility study of Pazopanib in combination with Paclitaxel and Carboplatin in patients with platinum-refractory/resistant ovarian, fallopian tube or peritoneal carcinoma. Study Coordinator: Ignace Vergote, U.Z. Leuven - Campus Gasthuisberg, Leuven
| 36 |
55102
ENGOT-EN2-DGCG | A phase III Trial of postoperative chemotherapy or no further treatment for patients with stage I-II medium or high risk endometrial cancer. Study Coordinators: Frederic Amant, U.Z. Leuven - Campus Gasthuisberg, Leuven Mansoor Raza Mirza, Rigshospitalet, Copenhagen
| 678 |
55994
| Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs.
concomitant radiotherapy and chemotherapy in
FIGO Ib2, IIa > 4 cm or IIb cervical cancer. Study Coordinators: Alessandro Colombo, Ospedale Alessandro Manzoni, Lecco Gemma Kenter, Academisch Medisch Centrum - Universiteit van Amsterdam, Amsterdam Fabio Landoni, Istituto Europeo Di Oncologia, Milano
| 686 |
| EORTC Head and Neck Cancer Group |
90111
24111 | Neoadjuvant afatinib based treatment strategies followed by surgery in squamous cell carcinoma of the head and neck: an EORTC NOCI-HNCG window study Study Coordinators: Lisa Licitra, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Jean-Pascal Machiels, Cliniques Universitaires St. Luc, Brussels
| 30 |
| EORTC Imaging Group |
20101
23101 | Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma (H11), a randomized phase III non-inferiority study of the EORTC Lymphoma Group and the Polish Lymphoma Research Group. Study Coordinator: Martin Hutchings, Rigshospitalet, Copenhagen
| 600 |
| EORTC Infectious Diseases Group |
65091
06093 | Empirical versus pre-emptive (diagnostic-driven) antifungal therapy of patients treated for haematological malignancies or receiving an allogeneic stem cell transplant. A therapeutic open label phase III strategy study of the EORTC Infectious Diseases and Leukemia Groups Study Coordinator: Peter Donnelly, Radboud University Nijmegen Medical Centre, Nijmegen
| 556 |
| EORTC Leukemia Group |
06083
HOVON 100 ALL | Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults. A prospective randomized trial. Study Coordinator: Jean-Pierre Marie, Assistance Publique - Hôpitaux de Paris - Hopital Saint Antoine AP-HP, Paris
| |
65091
06093 | Empirical versus pre-emptive (diagnostic-driven) antifungal therapy of patients treated for haematological malignancies or receiving an allogeneic stem cell transplant. A therapeutic open label phase III strategy study of the EORTC Infectious Diseases and Leukemia Groups Study Coordinator: Peter Donnelly, Radboud University Nijmegen Medical Centre, Nijmegen
| 556 |
| EORTC Lung Cancer Group |
08072
22074 | Concurrent once-daily versus twice-daily radiotherapy : A 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status Study Coordinator: Corinne Faivre-Finn, Christie NHS Foundation Trust, Manchester
| 532 |
08092
MAPPING | Double blind randomized phase III study of maintenance Pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy. Study Coordinator: Mary O'Brien, Royal Marsden Hospital - Sutton, Surrey, Sutton
| 587 |
22055
08053 | Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement - LUNG-ART Study Coordinator: Cecile Le Pechoux, Institut Gustave Roussy, Villejuif
| 700 |
| EORTC Lymphoma Group |
20101
23101 | Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma (H11), a randomized phase III non-inferiority study of the EORTC Lymphoma Group and the Polish Lymphoma Research Group. Study Coordinator: Martin Hutchings, Rigshospitalet, Copenhagen
| 600 |
| EORTC Melanoma Group |
18081
| Adjuvant peginterferon alpha-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group Study Coordinator: Alessandro Testori, Istituto Europeo Di Oncologia, Milano
| 1200 |
| EORTC Network of Core Institutions |
90091
10093 | TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) ("Treat CTC" trial) Study Coordinator: Michail Ignatiadis, Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels
| 250 |
90101
CREATE | Cross-tumoral Phase 2 clinical trial exploring crizotinib (PF-02341066) in patients with advanced tumors induced by causal alterations of ALK and/or MET ("CREATE") Study Coordinator: Patrick Schoeffski, U.Z. Leuven - Campus Gasthuisberg, Leuven
| 582 |
90111
24111 | Neoadjuvant afatinib based treatment strategies followed by surgery in squamous cell carcinoma of the head and neck: an EORTC NOCI-HNCG window study Study Coordinators: Lisa Licitra, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Jean-Pascal Machiels, Cliniques Universitaires St. Luc, Brussels
| 30 |
| EORTC Radiation Oncology Group |
08072
22074 | Concurrent once-daily versus twice-daily radiotherapy : A 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status Study Coordinator: Corinne Faivre-Finn, Christie NHS Foundation Trust, Manchester
| 532 |
22042
26042 | Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma : a Phase II and observation study Study Coordinator: Damien Weber, Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie, Geneve
| 54 |
22043
30041 | Immediate or early salvage post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus immediate or early salvage post-operative external radiotherapy alone in pT3a-b R0-1 cNOMO/pT2R1 cN0M0, Gleason score 5-10 prostatic carcinoma. A phase III study. Study Coordinators: Michel Bolla, CHU de Grenoble - La Tronche - Hôpital A. Michallon, Grenoble Steven Joniau, U.Z. Leuven - Campus Gasthuisberg, Leuven
| 600 |
22055
08053 | Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement - LUNG-ART Study Coordinator: Cecile Le Pechoux, Institut Gustave Roussy, Villejuif
| 700 |
22085
10083 | A randomized phase III study of radiation doses and fractionation schedules for ductal carcinoma in situ (DCIS) of the breast. Study Coordinator: Helen Westenberg, Arnhem's Radiotherapeutisch Instituut, Arnhem
| 610 |
26053
22054 | Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON intergroup trial. Study Coordinators: Brigitta Baumert, MediClin Robert Janker Klinik, Bonn Martin J. van den Bent, Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam
| 748 |
26062
22061 | A randomized phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients Study Coordinator: Alba Brandes, Ospedale Bellaria, Bologna
| 560 |
40084
22084 | A phase III trial evaluating both Erlotinib and Chemoradiation as adjuvant treatment for patients with resected head of pancreas adenocarcinoma Study Coordinator: Jean-Luc Van Laethem, Hôpitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme, Brussels
| 950 |
62092
22092 | A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with Retroperitoneal sarcomas (RPS) - STRASS Study Coordinator: Sylvie Bonvalot, Institut Gustave Roussy, Villejuif
| 256 |
| EORTC Soft Tissue and Bone Sarcoma Group |
62092
22092 | A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with Retroperitoneal sarcomas (RPS) - STRASS Study Coordinator: Sylvie Bonvalot, Institut Gustave Roussy, Villejuif
| 256 |